13 results about "Endometrium thickness" patented technology

A device adapted to monitor the follicles and to assess the thickness of the endometrium of a subject, comprises: a) an elongated member having a tip that houses an ultrasound probe; b) a handle adapted to be held in the hand of a subject; and c) a mechanism suitable to angularly displace said handle relative to said elongated member.

The application discloses a mesenchymal stem cell preparation and application thereof in thin endometrium repair, and comprises the following steps: adding Enterococcus durans CGMCC 1.3249 and Bacillus subtilis CGMCC 1.15792 supernatant as effective components into cultured mesenchymal stem cells; and the stem cell preparation obtained by the method can effectively restore the endometrial thickness of mice, increase the number of glands, and improve the pregnancy rate of the thin endometrium mice.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating polycystic ovarian syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from Chinese yam, semen cuscutae, pulp of dogwood fruit, radix glehniae, radix scrophulariae, lily, rhizoma polygonati, tortoise shell, cistanche deserticola, lotus seed and raspberry, has the effects of tonifying kidney and replenishing essence, nourishing yin and blood, replenishing qi and tonifying spleen, and benefiting uterus and accommodating fetus, and is mainly used for treating the polycystic ovarian syndrome. Research results show that the traditional Chinese medicine composition can significantly improve the sex hormone level of a patient with the polycystic ovarian syndrome, increase the endometrial thickness, improve the ovarian function and improve the endometrial receptivity, the ovulation rate and the pregnancy rate. Therefore, the traditional Chinese medicine composition has important clinical significance and wide market application prospects.

The invention discloses a traditional Chinese medicine composition for treating infertility. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: red ginseng, pseudo-ginseng, fructus corni, fructus lycii, angelica sinensis, Chinese yam, poria cocos, dragon's blood, ligusticum wallichii, carthamus tinctorius, teasel root, fructus alpiniae oxyphyllae, radix cyathulae, pawpaw, cynomorium songaricum, fleece-flower root, wild gastrodia elata, combined spicebush root, hippocampus, cinnamon, semen cuscutae, eucommia ulmoides, glossy privet fruit, fenugreek, tribulus terrestris, lycium ruthenicum and native copper. , fructus rosae laevigatae and magnetite. Compared with similar medicines in the market, the traditional Chinese medicine composition can effectively improve related indexes of reproduction of patients, increase the thickness of endometrium, promote follicular development, adjust the menstrual cycle and improve the semen quality, so that the pregnancy condition is improved.

The invention belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition for assisting pregnancy and implantation in a test tube and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following medicinal materials: teasel root, parasitic loranthus, semen cuscutae, radix paeoniae alba, liquorice, divaricate saposhnikovia root, roasted rhizoma atractylodis macrocephalae, pericarpium citri reticulatae, ramie root, scutellaria baicalensis, Chinese yam, fructus amomi, coptis chinensis, dogwood, radix rehmanniae preparata, folium mori, bamboo shavings and loofah sponge charcoal. The traditional Chinese medicine composition can regulate spleen and kidney deficiency states, improve ovarian blood flow, improve serum sex hormone level, increase endometrial thickness and vascular endothelial growth factor expression, contribute to endometrial growth, improve endometrial receptivity, assist implantation and development of reproductive embryos and improve pregnancy success rate of patients, and has good application prospects. The traditional Chinese medicine composition has more obvious effect on patients with ovarian reserve function decline, and is worthy of clinical popularization and application.

The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving endometrial receptivity, which is composed of the following components in parts by mass: Xianlingpi 15-25 parts, Cistanche 15-25 parts, Shanyurou 15-25 parts, Rhizoma Rehmanniae Preparata 15-25 parts, Radix Paeoniae Alba 15-25 parts, Atractylodes 15-25 parts, Spatholobus suberectus 15-25 parts, Salvia miltiorrhiza 10-20 parts, Rhizoma Cyperi 10-20 parts. The traditional Chinese medicine composition has the effects of tonifying kidney and generating essence, invigorating spleen and replenishing qi and blood, soothing liver and regulating qi, and activating blood and dredging collaterals, can up-regulate the expression of endometrial hormone receptors ERbeta and PR, enhance endometrial blood perfusion, increase endometrial thickness, improve endometrial receptivity, and thus improve the success rate of embryo implantation.

The invention provides a pharmaceutical preparation for repairing endometrial injury, and belongs to the technical field of biomedicine. The pharmaceutical preparation takes improved polypeptide as an active ingredient, and the amino acid sequence of the improved polypeptide is shown as SEQ ID NO.5. Experimental results show that the polypeptide can significantly promote proliferation and migration of human endometrial stromal cells, still maintains low cytotoxicity under high concentration, and shows excellent safety. Furthermore, in a rat endometrial mechanical injury model, the preparation can obviously increase the endometrial thickness, improve the Ki-67 positive cell rate, enhance the proliferation activity of endometrial cells and promote the repair of damaged tissues. Compared with the original polypeptide, the preparation disclosed by the invention shows unexpected technical effects in the aspects of repairing activity and safety, and has a good application prospect.

The present disclosure provides mRNA-based estrogen receptor regulatory compositions and their applications in estrogen low-responsive endometrial diseases, in particular, the use of mRNA of estrogen receptor alpha in the preparation of a drug for treating endometrial diseases. The scheme of the present disclosure can up-regulate the expression of estrogen receptor alpha (ERa) through in situ transfection in the uterine cavity, significantly increase the endometrial thickness, restore the endometrial structure and improve the fertility function.

This invention discloses a magnetic core-shell microsphere loaded with estrogen, its preparation method, and its application in the treatment of intrauterine adhesions. The outer phase consists of 1-10% sodium alginate, 1-3% polyvinyl alcohol, and magnetic nanoparticles, while the inner phase is a mixture of estrogen and natural oils at 1-10 ng / mL. Using a coaxial microfluidic electrospinning chip, a voltage of 6.5-8.5 kV is applied to the outer needle tip. After the droplet falls 7-9 cm, it is collected in a 2% calcium chloride solution for solidification, followed by washing and air drying to obtain microspheres with a particle size of 800-1200 μm. These microspheres exhibit magnetic responsiveness and sustained release in vitro for at least 24 hours. In a rat model of intrauterine adhesions, the endometrial thickness of the estrogen-loaded magnetic core-shell microsphere group was 522.33±32.51 μm, the number of glands was 41.67±5.03, and the collagen volume fraction was 0.52±0.03%, showing better efficacy than the estrogen-only group. This invention achieves targeted delivery and sustained release of drugs, providing a new solution for the treatment of intrauterine adhesions.

The present invention relates to a composition comprising beta core fragment hCG (βcf hCG) as an active ingredient for treating infertility. It has been confirmed that βcf hCG stimulates endometrial development in the early stage of pregnancy, is highly expressed in placental tissue, and is involved in maintenance of fetal development in the early stage of pregnancy. In addition, βcf hCG increases endometrial thickness, enhances expression of genes required for uterine development, and promotes growth of uterine-derived cell lines, thereby playing an important role in implantation and maintenance in the early stage of pregnancy. Accordingly, the composition can be usefully applied for treating recurrent miscarriage in female infertility and for improving embryo implantation rates during in vitro fertilization procedures, thereby increasing pregnancy success rates.

A device adapted to monitor the follicles and to assess the thickness of the endometrium of a subject, comprises: a) an elongated member having a tip that houses an ultrasound probe; and b) an ergonomic grip adapted to be held in the hand of a subject, said grip having a concave portion, the lowest point of which is located on an imaginary projection of the inner volume of said elongated member.

The present disclosure relates to a composition for treating infertility, which includes beta core fragment hCG (βcf hCG) as an active ingredient. The βcf hCG is identified to stimulate endometrial development in early pregnancy, is highly expressed in placental tissue, and is involved in maintaining fetal development in early pregnancy. The composition plays an important role in implantation and maintenance of early pregnancy by increasing the thickness of the endometrium, increasing the expression of genes necessary for uterine development, and promoting the growth of uterine-derived cell line. The composition can be usefully used to treat habitual miscarriage in female infertility, and to increase the success rate of pregnancy by improving the implantation rate of fertilized eggs in the process of in vitro fertilization.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.